exRNAdisease

General Information

Database ID:

exR0077780

RNA Name:

NME2

RNA Type:

mRNA

Chromosome:

chr17

Starnd:

Coordinate:

Start Site(bp):

51165435

End Site(bp):

51171747

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AAR2	chr20	36236459	36270918	+
AASDHPPT	chr11	106075501	106098699	+
ABHD6	chr3	58237532	58295693	+
AC004832.3	chr22	30409255	30428990	+
AC005258.1	chr19	2269525	2341172	+
AC006030.1	chr2	74211604	74363377	-
AC010422.3	chr19	12643831	12648397	-
AC104472.3	chr3	155763043	155854442	-
AC120057.2	chr17	7240427	7244635	-
AC131160.1	chr3	183815568	183884889	-
AC139530.2	chr17	81703371	81720539	+
ACACA	chr17	37084992	37406836	-
ACBD6	chr1	180269653	180502954	-
ACIN1	chr14	23058564	23095614	-
ACTB	chr7	5527148	5563784	-
ACTG1	chr17	81509971	81523847	-
ACVR2B	chr3	38453890	38493142	+
ADAR	chr1	154582057	154628013	-
ADAT1	chr16	75596981	75623300	-
ADGRG6	chr6	142301854	142446266	+
AKAP1	chr17	57085092	57121346	+
AKAP8L	chr19	15380050	15419141	-
AKAP9	chr7	91940867	92110673	+
AKIRIN1	chr1	38991276	39006059	+
AKR1A1	chr1	45550543	45570049	+
AL133352.1	chr10	100505628	100529881	-
AL513165.2	chr9	37512547	37592469	-
AL590764.2	chrX	71103987	71111575	-
ALDH2	chr12	111766887	111817532	+
ALDOA	chr16	30064164	30070457	+

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-206	chr6	52144401	52144422	+
hsa-miR-302c-3p	chr4	112648366	112648388	-

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC004224.2	chr16	3458071	3515564	+
AC020915.3	chr19	58257270	58278808	-
AC132217.1	chr11	2129121	2129964	-
AD000090.1	chr19	35557956	35581954	+

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference